RECRUITING

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma

Talk to us

Conditions

GliomaRecurrent Glioma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.

Official Title

Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol

Quick Facts

Study Start:2025-09-12
Study Completion:2028-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07074756

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥ 18 years
  2. * Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.
  3. * NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor.
  4. * NOTE: Any number of prior recurrences is permitted
  5. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60
  6. * Expected survival ≥ 6 months in the opinion of treatment team
  7. * Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
  8. * Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only
  9. * Provide written informed consent
  10. * Ability to complete assessments and questionnaires by themselves or with assistance
  1. * Pregnant or nursing, imprisoned, or lacking capacity for understanding
  2. * Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings

Contacts and Locations

Study Contact

Clinical Trials Referral Office
CONTACT
855-776-0015
mayocliniccancerstudies@mayo.edu

Principal Investigator

Ugur T. Sener, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Ugur T. Sener, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-12
Study Completion Date2028-08-31

Study Record Updates

Study Start Date2025-09-12
Study Completion Date2028-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • Glioma
  • Recurrent Glioma